It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

While there was no change in disability-free survival, the results should impact guidelines, says François Mach.

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

As the first trial of these valve interventions to impact HF hospitalization and mortality, it “feels like a COAPT-like ...

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.